Reviewed Mar 2026 | PubMed sources
Active Market
Spain is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Tirzepatide vs AOD-9604: Head-to-Head Comparison

Tirzepatide is one of the most effective weight loss drugs ever developed, with FDA approval and ~20%+ weight loss in trials. AOD-9604 is an hGH fragment that failed clinical trials for obesity. The evidence gap between these two is enormous.

Approved Comparison Routing

Approved options in this comparison

A
Tirzepatide

Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Tirzepatide with a provider?

Tirzepatide is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Tirzepatide Next Steps

ES selected - using US-first conversion assets

Side-by-Side Comparison

DimensionTirzepatideAOD-9604
Evidence LevelPhase III trials, FDA-approvedFailed Phase IIb/III trials
FDA StatusFDA-approved for T2D and obesityNot approved for any indication
MechanismDual GIP/GLP-1 receptor agonisthGH fragment (176-191) targeting fat metabolism
Weight Loss Efficacy~20-22.5% body weight lossNo significant efficacy demonstrated in trials
Side EffectsGI effects (nausea, vomiting, diarrhea)Minimal reported side effects
CostVery high (branded pharmaceutical)Low (research peptide pricing)
Evidence Level
Tirzepatide
Phase III trials, FDA-approved
AOD-9604
Failed Phase IIb/III trials
FDA Status
Tirzepatide
FDA-approved for T2D and obesity
AOD-9604
Not approved for any indication
Mechanism
Tirzepatide
Dual GIP/GLP-1 receptor agonist
AOD-9604
hGH fragment (176-191) targeting fat metabolism
Weight Loss Efficacy
Tirzepatide
~20-22.5% body weight loss
AOD-9604
No significant efficacy demonstrated in trials
Side Effects
Tirzepatide
GI effects (nausea, vomiting, diarrhea)
AOD-9604
Minimal reported side effects
Cost
Tirzepatide
Very high (branded pharmaceutical)
AOD-9604
Low (research peptide pricing)

Peptide Overviews

Tirzepatide

AFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Weight LossFDA Approved
View full Tirzepatide profile →

AOD-9604

CPreclinical

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) originally developed for obesity treatment. It has been explored as a lipolytic agent in research but has not received FDA approval or GRAS status for any use.

Weight LossNot Approved
View full AOD-9604 profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Tirzepatide vs AOD-9604: FAQ